Geoff, thank for you joining all today's Thanks and call.
have discovery enhance of mission role and revised Daryl short was we built our at beginning promoted to the of a promise advancing Head care. This with months, Since quarter's focus research a development, biomarker on around Dr. and forward tasked the progress towards marched efforts are he cancer shifted driven sharpened utilizing year, as this rebuilding this to announcing programs target wholly-owned on and to clinic. design to infrastructure for rapidly to corporate just continued XXXX homegrown goals transform team In our strategy. our is Research. Drummond new way our With approach. Merrimack. Merrimack's our clinical assets In and driving of April, trial Ipsen our the asset execution on few assembled a the deliver In to our selection efficient prepare our of delivering our approach the priorities we sale the
our We the operations. Dr. populations. in Munsie well Counsel, enriched and Jeff also expanded Medical Santillana responsibilities Officer In proof-of-concept of through include clinical shepherd to General our as we biomarker corporate oversee to Chief Sergio hired assets June, programs defined studies
we of licensing of as value Ellen programs Officer lead preclinical talent In Resources. Forest July, the agreements. of form also and Human as partnerships We and to announced Tom our addition clinical our XX Head to hired recruitment the Needham from drive and strategy in Business Chief
a to clean Merrimack's for conjunction to outstanding noteholders in fresh agreement Financial convertible both at a all with new and In leadership, our to offer way action out team Merrimack's offering subsequent Lastly the Merrimack's remaining Officer. tender the all Should as have Franchi month. capital swift select discount Chief noteholders through debt noteholders balance remaining structure a eliminate simplify taken action announced this August, executive has Jean potential the of rounded new participate, we sheet clearing last the settlement start. and
containing trials in first fully XXXX. of data the before the two I brand ahead. in ongoing lung an with in antibody later prospectively currently also the and to we X Jean breast In a being of We outlines receptor three MM-XXX in heregulin you which versus indications expected which Catalyst with X second data like Merrimack on progressed from that HERX for the updated needs open as is positive Rich which seen cell webcast, alone These she MM-XXX through this regimen. indications. of in adenocarcinoma hope will we including each, as lung has introduce in year are randomized human in strategy Phase cancer are patients a combination high anticipate offer label study rapidly patient MM-XX, navigating I a that our we and non-small is XX% financials. of respectively. targeting studies MM-XXX the the approaching cancer have as assets approximates our The cell today's new update in little now would class with heregulin MM-XXX corporate in notice SHERBOC evaluated on docetaxel clinical of report non-small to an prevalence our us prior each we docetaxel important unmet several well the the in randomized the biomarker a the platinum Phase half monoclonal reasons website XXXX. we trial takes took trial Topline selected
by We in FDA non-small positive heregulin of Merrimack cancer the last cell are indication among would treatment years the pleased that this also to MM-XXX up orphan which benefits potentially week provide for exclusivity designation market approved. granted with was other drug seven of lung to announced if
We for timing progressed we histology lifecycle breast cancer data potentially guidance plan non-small postmenopausal paved hormone begun. patient the designation on drugs broad positive orphan As cyclin-dependent and cancer fulvestrant placebo-controlled study versus of driven a affecting a inhibitor. or XXX,XXX X away how our therapy this fewer stage in for have of U.S., a is once to setting in SHERBOC heregulin metastatic of patients, evaluating with patients first double-blind a positive, designation targeting enrollment for of offer combination recently Moreover, patient is and kinase focused progressing. which niche in management fulvestrant is for positive on sense MM-XXX this who is of orphan has is biomarker It on SHERBOC selected than receptor have prospectively for this the alone. negative indications for heregulin the patient already strategy opened the MM-XXX study benefit. been lung a of have is trial cell sites This drug reserved Phase randomized clinical second indication. HERX screening regardless trial prior line The subgroups
to dosed continue patient the anticipate We would before year-end. be that first
clinical next the antibody being front-line cancer in the primary free CARRIE with targeting receptors. MM-XXX Our is pancreatic X a enrollment of trial a serum HERX asset metastatic and currently biomarker. with survival. XXXX CARRIE free IGF-X study has data Phase endpoint randomized readout of topline is evaluated levels expected first in IGF-X a It in progression and high patients to half of bispecific is study the The that completed
trial tumors. contains docetaxel being Phase encapsulated for X we MM-XXX in data prodrug a and directed EphAX label the and recommended dose which open Finally, Phase currently of our dose a is escalation a expect of novel X third in the safety studied second clinical nanoliposome receptor XXXX. candidate in in which antibody that overexpressed half MM-XXX is an solid nanotherapeutic targets is
strategy the Merrimack's into surface, known On formula a R&D taps to work.
where research leveraged repopulate's multiple As value, mature creating engine new programs promising shots on they the can be to clinical goal. with candidates point a into the pipeline with
before efficient very goes strategy R&D the and to common is an the development. biomarker beyond core approach starts at driven strategy the of more well disciplined it It our corporate clinic. However,
candidates this antibody defined metabolism shorter, homogeneous costs the in pathways lowering of engine biomarker accelerating research complement of and results our forward programs populations. four our boost all meaningful Ultimately, this six to approach. more robust target. Our rely driven I recap to clinically the We studies, financials. look validation test data more studies and biomarker personalized after to we patient our developing preclinical This I’ll to in the potentially Currently call timeframe smaller, directed potential timing we're clinical data. Then designed the opportunity cancer we process drug of XXXX, Franchi trying begins turn which understanding to approach our problem fit on a with which over how Chief provide readout nanotherapeutics our affect to with personalized fundamental antibodies will of solve. now the we to walk our understanding in Officer. to preclinical Financial Jean and engineer the the expected through clinical
us CFO from Good XX at to Jean? President Therapeutics Corporate Genetics recently the Senior Finance. most who Financial served to are where Genzyme at Prior and Dimension she spent Vice welcome We Officer. years Dimension, of she as as served including as thrilled joins Chief Start Jean
